{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IMSA101",
    "query": {
      "intervention": "IMSA101"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T03:18:31.914Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04020185",
      "title": "Safety and Efficacy Study of IMSA101 in Refractory Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "IMSA101",
          "type": "DRUG"
        },
        {
          "name": "Immune checkpoint inhibitor (ICI)",
          "type": "DRUG"
        },
        {
          "name": "Immuno-oncology (IO) therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmuneSensor Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2019-09-23",
      "completion_date": "2023-09-15",
      "has_results": true,
      "last_update_posted_date": "2024-12-11",
      "last_synced_at": "2026-09-02T03:18:31.914Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04020185"
    },
    {
      "nct_id": "NCT05846646",
      "title": "Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oligometastatic Disease"
      ],
      "interventions": [
        {
          "name": "IMSA101",
          "type": "DRUG"
        },
        {
          "name": "Immune checkpoint inhibitor",
          "type": "DRUG"
        },
        {
          "name": "PULSAR",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "ImmuneSensor Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2023-06-28",
      "completion_date": "2024-09-16",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-09-02T03:18:31.914Z",
      "location_count": 9,
      "location_summary": "Irvine, California • Kansas City, Kansas • New Brunswick, New Jersey + 5 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05846646"
    },
    {
      "nct_id": "NCT06026254",
      "title": "A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "IMSA101",
          "type": "DRUG"
        },
        {
          "name": "Immune Checkpoint Inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmuneSensor Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2023-09-15",
      "completion_date": "2025-09",
      "has_results": false,
      "last_update_posted_date": "2024-11-18",
      "last_synced_at": "2026-09-02T03:18:31.914Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • La Jolla, California",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06026254"
    },
    {
      "nct_id": "NCT05846659",
      "title": "Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oligoprogressive"
      ],
      "interventions": [
        {
          "name": "IMSA101",
          "type": "DRUG"
        },
        {
          "name": "Immune checkpoint inhibitor",
          "type": "DRUG"
        },
        {
          "name": "PULSAR",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "ImmuneSensor Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2023-07-07",
      "completion_date": "2024-11-20",
      "has_results": true,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-09-02T03:18:31.914Z",
      "location_count": 14,
      "location_summary": "Irvine, California • Los Angeles, California • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05846659"
    },
    {
      "nct_id": "NCT06601296",
      "title": "Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Renal Cell Carcinoma ( mRCC)",
        "OligoProgressive Metastatic Disease"
      ],
      "interventions": [
        {
          "name": "IMSA101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2025-04-01",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-09-02T03:18:31.914Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06601296"
    }
  ]
}